Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.80 |
| ▸ | ATM | Q13315 | 2/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.80 |
| ▸ | TAS2R31 | P59538 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.76 |
| ▸ | CA12 | O43570 | 3/20 | 0.76 |
| ▸ | CA4 | P22748 | 3/20 | 0.76 |
| ▸ | CA7 | P43166 | 3/20 | 0.76 |
| ▸ | DPP4 | P27487 | 2/20 | 0.76 |
| ▸ | GSK3B | P49841 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isosakutanetin SCHEMBL31128790 | 1.00 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| Isosakutanetin SCHEMBL676015 | 1.00 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| Isosakutanetin SCHEMBL29358328 | 1.00 | CYP1A1 (1.00) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| SCHEMBL16710297 | 0.94 | CYP19A1 (0.90) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| SCHEMBL16710295 | 0.94 | CYP19A1 (0.90) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| Isosakutanetin SCHEMBL2146746 | 0.90 | CYP1A1 (0.82) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| Naringenin SCHEMBL7668757 | 0.90 | CYP1A1 (0.82) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| SCHEMBL13906136 | 0.89 | CYP1A1 (0.80) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| Alpinetin SCHEMBL30741428 | 0.89 | CYP1A1 (0.80) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT | |
| Alpinetin SCHEMBL29580312 | 0.89 | CYP1A1 (0.80) | CYP1A1CYP1A2CYP1B1CYP19A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4617293-A | Flavonoid phosphate salts of aminoglycoside antibiotics | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | claimed |
| US-20200085956-A1 | NOVEL ANTIOXIDANTS FOR COSMETICS AND PHARMACEUTICAL COMPOSITIONS CONTAINING GLYCEROL ALKYL ETHERS | SACHEM, INC. | 2020-03-19 | — | — | US | disclosed |
| US-10435673-B2 | Method for the biotechnological production of flavonoids | SYMRISE AG (DE) | 2019-10-08 | — | — | US | disclosed |
| WO-2018125734-A1 | NOVEL ANTIOXIDANTS FOR COSMETICS AND PHARMACEUTICAL COMPOSITIONS CONTAINING GLYCEROL ALKYL ETHERS | SACHEM, INC. (US) | 2018-07-05 | — | — | WO | disclosed |
| US-20180135029-A1 | METHOD FOR THE BIOTECHNOLOGICAL PRODUCTION OF FLAVONOIDS | SYMRISE AG (DE) | 2018-05-17 | — | — | US | disclosed |
| US-20180135029-A1 | METHOD FOR THE BIOTECHNOLOGICAL PRODUCTION OF FLAVONOIDS | SYMRISE AG (DE) | 2018-05-17 | — | — | US | disclosed |
| US-9415034-B2 | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2016-08-16 | — | — | US | disclosed |
| US-20160184298-A1 | INHIBITORS AND ENHANCERS OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B (UGT2B) | NAT DEFENSE MEDICAL CT (TW) | 2016-06-30 | — | — | US | disclosed |
| EP-3002335-A1 | Process for the biotechnological production of flavonoids | Symrise AG (DE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2984077-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING SWEET TASTE | Chromocell Corporation (US) | 2016-02-17 | — | — | EP | disclosed |
| WO-2006020163-A1 | SKIN CARE COMPOSITION CONTAINING A FLAVONOID AND VITAMIN B3 | THE PROCTER & GAMBLE COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060018861-A1 | Skin care composition | PROCTER & GAMBLE COMPANY, THE | 2006-01-26 | — | — | US | disclosed |
| US-20060018858-A1 | Skin care composition | THE PROCTER & GAMBLE COMPANY | 2006-01-26 | — | — | US | disclosed |
| US-20060018860-A1 | Skin care composition | PROCTER & GAMBLE COMPANY, THE | 2006-01-26 | — | — | US | disclosed |
| US-20060018862-A1 | Substrate based skin care device | PROCTER & GAMBLE COMPANY, THE | 2006-01-26 | — | — | US | disclosed |
| EP-1286706-A2 | GAMMA IRRADIATION OF PROTEIN-BASED PHARMACEUTICAL PRODUCTS | The American National Red Cross (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001087357-A2 | GAMMA IRRADIATION OF PROTEIN-BASED PHARMACEUTICAL PRODUCTS | THE AMERICAN NATIONAL RED CROSS (US) | 2001-11-22 | — | — | WO | disclosed |
| US-4617293-A | Flavonoid phosphate salts of aminoglycoside antibiotics | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1986-10-14 | — | — | US | disclosed |
| EP-0065123-B1 | HARDLY SOLUBLE SALTS OF AMINOGLYCOSIDE ANTIBIOTICS | MERCK PATENT GmbH (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0065123-A1 | Hardly soluble salts of aminoglycoside antibiotics | MERCK PATENT GmbH (DE) | 1982-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060018860-A1 | Skin care composition | CUTA, C1QBP, FLNB | CYP1A1 321/4885CYP1A2 823/4885CYP1B1 69/4885 |
| US-20200085956-A1 | NOVEL ANTIOXIDANTS FOR COSMETICS AND PHARMACEUTICAL COMPOSITIONS CONTAINING GLYCEROL ALKYL ETHERS | ACOX3, GK, ACAD10 | CYP1A1 581/4885CYP1A2 829/4885CYP1B1 508/4885 |
| US-20060018862-A1 | Substrate based skin care device | CUTA, TYR, PROC | CYP1A1 128/4885CYP1A2 334/4885CYP1B1 120/4885 |
| US-20160184298-A1 | INHIBITORS AND ENHANCERS OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE 2B (UGT2B) | UGT2B7, UGT2B17, UGT1A10 | CYP1A1 28/4885CYP1A2 26/4885CYP1B1 16/4885 |
| US-20060018858-A1 | Skin care composition | CUTA, FLNB, CYP24A1 | CYP1A1 252/4885CYP1A2 417/4885CYP1B1 41/4885 |
| US-20060018861-A1 | Skin care composition | CUTA, SERPINB6, FLNB | CYP1A1 381/4885CYP1A2 666/4885CYP1B1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.